
By Marketwired . | Article Rating: |
|
April 1, 2014 06:00 AM EDT | Reads: |
141 |

FOSTER CITY, CA -- (Marketwired) -- 04/01/14 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 13th Needham Healthcare Conference at 5:00 pm ET on Tuesday, April 8, 2014, at the Westin NY Grand Central Hotel in New York City.
To access the live audio webcast of these presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com, under the Calendar of Events tab. A replay of the webcast will be available one hour after the conclusion of the live events.
About SciClone
SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets, including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Through its promotion business with pharmaceutical partners, SciClone markets multiple branded products in China which are therapeutically differentiated. The Company has successfully in-licensed products with the potential to become future market leaders and to drive the Company's long-term growth. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit www.sciclone.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.
Corporate Contacts
Wilson W. Cheung
Chief Financial Officer
650.358.3434
[email protected]
Jane Green
Investors/Media
650.358.1447
[email protected]
Published April 1, 2014 Reads 141
Copyright © 2014 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
More Stories By Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.
![]() Apr. 20, 2018 11:30 PM EDT Reads: 13,119 |
By Liz McMillan ![]() Apr. 20, 2018 11:30 PM EDT Reads: 4,574 |
By Yeshim Deniz Apr. 20, 2018 11:15 PM EDT Reads: 2,321 |
By Elizabeth White ![]() Apr. 20, 2018 11:00 PM EDT Reads: 3,509 |
By Liz McMillan ![]() Apr. 20, 2018 10:45 PM EDT Reads: 6,478 |
By Pat Romanski ![]() Apr. 20, 2018 10:45 PM EDT Reads: 3,893 |
By Liz McMillan ![]() Apr. 20, 2018 10:30 PM EDT Reads: 22,398 |
By Elizabeth White ![]() Apr. 20, 2018 10:15 PM EDT Reads: 6,172 |
By Pat Romanski Apr. 20, 2018 10:00 PM EDT Reads: 4,807 |
By Yeshim Deniz Apr. 20, 2018 10:00 PM EDT Reads: 2,484 |
By Pat Romanski ![]() Apr. 20, 2018 09:30 PM EDT Reads: 6,743 |
By Elizabeth White ![]() Apr. 20, 2018 09:15 PM EDT Reads: 3,517 |
By Elizabeth White ![]() Apr. 20, 2018 08:45 PM EDT Reads: 1,036 |
By Elizabeth White ![]() Apr. 20, 2018 08:00 PM EDT Reads: 8,945 |
By Yeshim Deniz Apr. 20, 2018 08:00 PM EDT Reads: 610 |